HIV AND HEPATITIS POLICY INSTITUTE
HIV AND HEPATITIS POLICY INSTITUTE filed a registration for HIV AND HEPATITIS POLICY INSTITUTE on September 29, 2025.
Lobbying for HIV AND HEPATITIS POLICY INSTITUTE · Patient advocacy
Budget and appropriations for domestic HIV and hepatitis prevention through the CDC and HIV treatment through HRSA; authorizing legislation and Executive Branch programs to support access to HIV prevention medication, treatment, and testing services and viral hepatitis treatment and testing services; and legislation and Executive Branch programs impacting patient access to affordable healthcare and prescription drugs offered through Medicaid, Medicare, and the private insurance market.
Budget and appropriations for domestic HIV and hepatitis prevention through the CDC and HIV treatment through HRSA; authorizing legislation and Executive Branch programs to support access to HIV prevention medication, treatment, and testing services and viral hepatitis treatment and testing services; and legislation and Executive Branch programs impacting patient access to affordable healthcare and prescription drugs offered through Medicaid, Medicare, and the private insurance market.
Budget and appropriations for domestic HIV and hepatitis prevention through the CDC and HIV treatment through HRSA; authorizing legislation and Executive Branch programs to support access to HIV prevention medication, treatment, and testing services and viral hepatitis treatment and testing services; and legislation and Executive Branch programs impacting patient access to affordable healthcare and prescription drugs offered through Medicaid, Medicare, and the private insurance market.
Budget and appropriations for domestic HIV and hepatitis prevention through the CDC and HIV treatment through HRSA; authorizing legislation and Executive Branch programs to support access to HIV prevention medication, treatment, and testing services and viral hepatitis treatment and testing services; and legislation and Executive Branch programs impacting patient access to affordable healthcare and prescription drugs offered through Medicaid, Medicare, and the private insurance market.
Budget and appropriations for domestic HIV and hepatitis prevention through the CDC and HIV treatment through HRSA; authorizing legislation and Executive Branch programs to support access to HIV prevention medication, treatment, and testing services and viral hepatitis treatment and testing services; and legislation and Executive Branch programs impacting patient access to affordable healthcare and prescription drugs offered through Medicaid, Medicare, and the private insurance market.